Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> - Transitional Survey From the Preceding Drug-use Survey -

Completed

Conditions: Insomnia

Interventions: Drug: Ramelteon

First Posted Date: 2014-06-02

Last Posted Date: 2016-10-13

Lead Sponsor: Takeda

Target Recruit Count: 236

Registration Number: NCT02153086

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

Phase 1

Completed

Conditions: Dose Finding Study

Interventions: Drug: Placebo
Drug: TAK-058 (ENV8058)

First Posted Date: 2014-06-02

Last Posted Date: 2015-12-17

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT02153099

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

Phase 2

Completed

Conditions: Norovirus

Interventions: Biological: GI.1/GII.4 (15/15)
Biological: GI.1/GII.4 (15/50)
Biological: GI.1/GII.4 (50/50)
Biological: GI.1/GII.4 (50/150)
Drug: Placebo

First Posted Date: 2014-06-02

Last Posted Date: 2019-04-01

Lead Sponsor: Takeda

Target Recruit Count: 840

Registration Number: NCT02153112

Locations: 🇫🇮
Oulun Rokotetutkimusklinikka, Oulu, Finland
🇫🇮
Turun Rokotetutkimusklinikka, Turku, Finland
🇵🇦
CEVAXIN, Panama, Panama

and more 9 locations

Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination

Completed

Conditions: Measles/Rubella

Interventions: Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)

First Posted Date: 2014-05-30

Last Posted Date: 2017-01-31

Lead Sponsor: Takeda

Target Recruit Count: 3493

Registration Number: NCT02151773

Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

Completed

Conditions: Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions

Interventions: Drug: Lansoprazole

First Posted Date: 2014-05-30

Last Posted Date: 2016-02-23

Lead Sponsor: Takeda

Target Recruit Count: 1120

Registration Number: NCT02151786

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

Phase 2

Completed

Conditions: Norovirus Prevention

Interventions: Biological: Norovirus Bivalent VLP Vaccine
Drug: Placebo (Saline)

First Posted Date: 2014-05-20

Last Posted Date: 2017-08-21

Lead Sponsor: Takeda

Target Recruit Count: 454

Registration Number: NCT02142504

Locations: 🇺🇸
SNBL, Baltimore, Maryland, United States
🇺🇸
California Research Foundation, San Diego, California, United States
🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

and more 7 locations

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

Phase 1

Completed

Conditions: Dose Finding Study

Interventions: Drug: TAK-438
Drug: TAK-438 Placebo
Drug: Esomeprazole

First Posted Date: 2014-05-19

Last Posted Date: 2014-05-19

Lead Sponsor: Takeda

Target Recruit Count: 73

Registration Number: NCT02141698

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

Phase 1

Completed

Conditions: Erosive Esophagitis(EE)
Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: TAK-438
Drug: TAK-438 Placebo

First Posted Date: 2014-05-19

Last Posted Date: 2014-05-19

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT02141711

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Phase 1

Completed

Conditions: Hormone Treatment-naïve Participants With Prostate Cancer

Interventions: Drug: TAK-385

First Posted Date: 2014-05-19

Last Posted Date: 2018-11-19

Lead Sponsor: Takeda

Target Recruit Count: 43

Registration Number: NCT02141659

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Completed

Conditions: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

Interventions: Drug: Brentuximab vedotin (recombinant)

First Posted Date: 2014-05-15

Last Posted Date: 2020-07-13

Lead Sponsor: Takeda

Target Recruit Count: 292

Registration Number: NCT02139592

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy